Previous Close | 18.89 |
Open | 18.99 |
Bid | 13.52 x 800 |
Ask | 18.44 x 800 |
Day's Range | 18.35 - 19.09 |
52 Week Range | 16.02 - 36.95 |
Volume | |
Avg. Volume | 551,354 |
Market Cap | 1.47B |
Beta (5Y Monthly) | 1.53 |
PE Ratio (TTM) | 23.66 |
EPS (TTM) | 0.78 |
Earnings Date | May 02, 2022 - May 06, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.33 |
2021 report demonstrates focus on ESG initiatives supporting health equity, social justice, and sustainability SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its first environmental, social and governance (ESG) report, highlighting increased efforts to support a healthy, equitable and sustainable society. The report outlines actions taken to expand access to genetic testing, advance socia
Myriad Genetics (MYGN) continues to benefit from strong testing volumes, but forex remains a woe.
Healthcare providers can easily order Myriad’s genetic tests for the more than 250 million patients within Epic’s networkPartnership bolsters Myriad’s growth plan to scale customer-centric, tech-enabled commercial capabilities with over 600 EHR integrations this year SALT LAKE CITY, June 23, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a partnership with Epic, the industry leading healthcare software company,